Kathrin van Bremen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kathrin van Bremen has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
Jürgen K. Rockstroh
Bonn University Hospital Bonn Germany
3 shared publicationsChristoph Boesecke
Bonn University Hospital Bonn Germany
2 shared publications- Christoph Boesecke
Department of Medicine I, Bonn University Hospital, Bonn, Germany
2 shared publications Jan‐Christian Wasmuth
Bonn University Hospital Bonn Germany
2 shared publications- Jürgen Kurt Rockstroh
Department of Medicine I University Hospital Bonn Bonn Germany
2 shared publications Malte Monin
Bonn University Hospital Bonn Germany
2 shared publications
Latest Publications
- Open Access
HIV Care in Ukrainian Migrants in Two European Countries: All the Same?
Introduction: War in Ukraine prompted an enormous refugee influx into Europe, including approximately 4200 people with HIV. The unique healthcare features of Ukrainian refugees living with HIV were compared between two infectious disease departments in Bonn, Germany, and Szczecin, Poland. Methods: This is a retrospective study on 161 people living with HIV (PLWH) refugees from Ukraine seeking care in Bonn (n = 30) and Szczecin (n = 131) between April 2022 and May 2023. Demographic, virologic, immunologic, and coinfection data were analyzed. Results: The majority of the studied individuals were female: 64% (n = 84) in Szczecin and 60% (n = 18) in Bonn. The main HIV transmission mode was heterosexual sex in 73.5% (n = 114). All were on combined antiretroviral therapy (cART) on arrival, primarily on the TLD regimen (TDF/3TC/DTG) (68.4%, n = 106). In Germany, cART was most frequently switched to BIC/TAF/FTC in 83.4% (n = 25); in Poland, the most common combination was TDF/FTC + DTG (58%, n = 76). A prevalence of replicating hepatitis C was in 11.7% (n = 15), and that for chronic hepatitis B (HBV) was in 4.7% (n = 4). History of past tuberculosis was reported in 16.9% (n = 14, Poland, and n = 7, Germany). Follow-up after 6 months showed immunological reconstitution with a mean increase of CD4+ of 10 (IQR: −69.5–120.5) cells/µL in Poland and 51.5 (IQR: −22.5–135.5) cells/µL in Germany; p = 0.04. Virologic suppression (<40 HIV-RNA/mL) was high in care entry (n = 62; 98%) for Poland, and n = 26 (92.6%) for Germany, and suppression was achieved in the majority of patients in the 6-month control (89.7% in Poland vs. 95.7% in Germany). Conclusions: Health challenges posed by war migration extend beyond HIV to coinfections as HBV, HCV, and tuberculosis give an indication for a broader search for coinfections, often less common in the new country.
Open AccessHIV Care in Ukrainian Migrants in Two European Countries: All the Same?
Introduction: War in Ukraine prompted an enormous refugee influx into Europe, including approximately 4200 people with HIV. The unique healthcare features of Ukrainian refugees living with HIV were compared between two infectious disease departments in Bonn, Germany, and Szczecin, Poland. Methods: This is a retrospective study on 161 people living with HIV (PLWH) refugees from Ukraine seeking care in Bonn (n = 30) and Szczecin (n = 131) between April 2022 and May 2023. Demographic, virologic, immunologic, and coinfection data were analyzed. Results: The majority of the studied individuals were female: 64% (n = 84) in Szczecin and 60% (n = 18) in Bonn. The main HIV transmission mode was heterosexual sex in 73.5% (n = 114). All were on combined antiretroviral therapy (cART) on arrival, primarily on the TLD regimen (TDF/3TC/DTG) (68.4%, n = 106). In Germany, cART was most frequently switched to BIC/TAF/FTC in 83.4% (n = 25); in Poland, the most common combination was TDF/FTC + DTG (58%, n = 76). A prevalence of replicating hepatitis C was in 11.7% (n = 15), and that for chronic hepatitis B (HBV) was in 4.7% (n = 4). History of past tuberculosis was reported in 16.9% (n = 14, Poland, and n = 7, Germany). Follow-up after 6 months showed immunological reconstitution with a mean increase of CD4+ of 10 (IQR: −69.5–120.5) cells/µL in Poland and 51.5 (IQR: −22.5–135.5) cells/µL in Germany; p = 0.04. Virologic suppression (<40 HIV-RNA/mL) was high in care entry (n = 62; 98%) for Poland, and n = 26 (92.6%) for Germany, and suppression was achieved in the majority of patients in the 6-month control (89.7% in Poland vs. 95.7% in Germany). Conclusions: Health challenges posed by war migration extend beyond HIV to coinfections as HBV, HCV, and tuberculosis give an indication for a broader search for coinfections, often less common in the new country.
- Open Access
- 15 May 2023
- Published by Wiley in Liver International
- Vol. 43 (7) , 1427-1439
Prognostic value of non‐invasive scores based on liver stiffness measurement, spleen diameter and platelets in HIV‐infected patients
Background and Aims: People living with HIV (PLWH) are at high risk for advanced chronic liver disease and related adverse outcomes. We aimed to validate the prognostic value of non‐invasive scores based on liver stiffness measurement (LSM) and on markers of portal hypertension (PH), namely platelets and spleen diameter, in PLWH.Methods: We combined data from eight international cohorts of PLWH with available non‐invasive scores, including LSM and the composite biomarkers liver stiffness‐spleen size‐to‐platelet ratio score (LSPS), LSM‐to‐Platelet ratio (LPR) and PH risk score. Incidence and predictors of all‐cause mortality, any liver‐related event and classical hepatic decompensation were determined by survival analysis, controlling for competing risks for the latter two. Non‐invasive scores were assessed and compared using area under the receiver operating curve (AUROC).Results: We included 1695 PLWH (66.8% coinfected with hepatitis C virus). During a median follow‐up of 4.7 (interquartile range 2.8–7.7) years, the incidence rates of any liver‐related event, all‐cause mortality and hepatic decompensation were 13.7 per 1000 persons‐year (PY) (95% confidence interval [CI], 11.4–16.3), 13.8 per 1000 PY (95% CI, 11.6–16.4) and 9.9 per 1000 PY (95% CI, 8.1–12.2), respectively. The AUROC of LSM was similar to that of the composite biomarkers, ranging between 0.83 and 0.86 for any liver‐related event, 0.79–0.85 for all‐cause mortality and 0.87–0.88 for classical hepatic decompensation. All individual non‐invasive scores remained independent predictors of clinical outcomes in multivariable analysis.Conclusions: Non‐invasive scores based on LSM, spleen diameter and platelets predict clinical outcomes in PLWH. Composite biomarkers do not achieve higher prognostic performance compared to LSM alone.
- 15 May 2023
- Published by Wiley in Liver International
- Vol. 43 (7) , 1427-1439
Open AccessPrognostic value of non‐invasive scores based on liver stiffness measurement, spleen diameter and platelets in HIV‐infected patients
Background and Aims: People living with HIV (PLWH) are at high risk for advanced chronic liver disease and related adverse outcomes. We aimed to validate the prognostic value of non‐invasive scores based on liver stiffness measurement (LSM) and on markers of portal hypertension (PH), namely platelets and spleen diameter, in PLWH.Methods: We combined data from eight international cohorts of PLWH with available non‐invasive scores, including LSM and the composite biomarkers liver stiffness‐spleen size‐to‐platelet ratio score (LSPS), LSM‐to‐Platelet ratio (LPR) and PH risk score. Incidence and predictors of all‐cause mortality, any liver‐related event and classical hepatic decompensation were determined by survival analysis, controlling for competing risks for the latter two. Non‐invasive scores were assessed and compared using area under the receiver operating curve (AUROC).Results: We included 1695 PLWH (66.8% coinfected with hepatitis C virus). During a median follow‐up of 4.7 (interquartile range 2.8–7.7) years, the incidence rates of any liver‐related event, all‐cause mortality and hepatic decompensation were 13.7 per 1000 persons‐year (PY) (95% confidence interval [CI], 11.4–16.3), 13.8 per 1000 PY (95% CI, 11.6–16.4) and 9.9 per 1000 PY (95% CI, 8.1–12.2), respectively. The AUROC of LSM was similar to that of the composite biomarkers, ranging between 0.83 and 0.86 for any liver‐related event, 0.79–0.85 for all‐cause mortality and 0.87–0.88 for classical hepatic decompensation. All individual non‐invasive scores remained independent predictors of clinical outcomes in multivariable analysis.Conclusions: Non‐invasive scores based on LSM, spleen diameter and platelets predict clinical outcomes in PLWH. Composite biomarkers do not achieve higher prognostic performance compared to LSM alone.
- Open Access
- 20 October 2022
- Published by Wiley in HIV Medicine
- Vol. 23 (11) , 1209-1213
Impact of COVID‐19 on HIV late diagnosis in a specialized German centre
Background: The ongoing COVID‐19 pandemic has been impeding HIV diagnosis and treatment worldwide. Data on the impact of COVID‐19 on late diagnosis (LD) in Germany are lacking. Here we present novel data of a single‐centre German HIV cohort assessing LD during COVID‐19.Methods: This is a non‐interventional, single‐centre retrospective cohort assessing the rate of LD comparing HIV diagnoses pre‐COVID‐19 with those during the COVID‐19 pandemic. New diagnoses between 1 January 2019 and 1 February 2020 were classified as pre‐COVID‐19, and diagnoses between 1 February 2020 and 1 October 2021 were classified as during COVID‐19.Results: Between 1 January 2019 and 1 October 2021, 75 patients presented with newly diagnosed HIV infection, 34 pre‐COVID‐19 and 41 during COVID‐19. LD increased to 83% (n = 34/41) during COVID‐19 versus 59% (n = 20/34) pre‐COVID‐19, and CDC stage C3 rose to 44% (n = 18) versus 27%. Hospitalization rate increased to 49% (n = 20) during COVID‐19 versus 29% pre‐COVID‐19, and 12% (n = 5) presented with HIV‐associated neurological disease, whereas none were observed in the pre‐COVID‐19 group. The incidence of LD (p = 0.020), CD4 count < 350 cells/μL (p = 0.037) and < 200 cells/μL (p = 0.022) were statistically significantly associated with the ongoing COVID‐pandemic. An association with HIV transmission risk was borderline significant (p = 0.055).Conclusions: Despite comparable annual rates of new HIV diagnoses, LD has been increasing during the COVID‐19 pandemic, resulting in more opportunistic infections and higher hospitalization rates, possibly reflecting pandemic‐related shortages in HIV testing and care facilities. Maintaining HIV testing opportunities and access to treatment during a pandemic is crucial so as not to impede WHO elimination goals and so as to prevent an increase in AIDS‐related morbidity and mortality.
- 20 October 2022
- Published by Wiley in HIV Medicine
- Vol. 23 (11) , 1209-1213
Open AccessImpact of COVID‐19 on HIV late diagnosis in a specialized German centre
Background: The ongoing COVID‐19 pandemic has been impeding HIV diagnosis and treatment worldwide. Data on the impact of COVID‐19 on late diagnosis (LD) in Germany are lacking. Here we present novel data of a single‐centre German HIV cohort assessing LD during COVID‐19.Methods: This is a non‐interventional, single‐centre retrospective cohort assessing the rate of LD comparing HIV diagnoses pre‐COVID‐19 with those during the COVID‐19 pandemic. New diagnoses between 1 January 2019 and 1 February 2020 were classified as pre‐COVID‐19, and diagnoses between 1 February 2020 and 1 October 2021 were classified as during COVID‐19.Results: Between 1 January 2019 and 1 October 2021, 75 patients presented with newly diagnosed HIV infection, 34 pre‐COVID‐19 and 41 during COVID‐19. LD increased to 83% (n = 34/41) during COVID‐19 versus 59% (n = 20/34) pre‐COVID‐19, and CDC stage C3 rose to 44% (n = 18) versus 27%. Hospitalization rate increased to 49% (n = 20) during COVID‐19 versus 29% pre‐COVID‐19, and 12% (n = 5) presented with HIV‐associated neurological disease, whereas none were observed in the pre‐COVID‐19 group. The incidence of LD (p = 0.020), CD4 count < 350 cells/μL (p = 0.037) and < 200 cells/μL (p = 0.022) were statistically significantly associated with the ongoing COVID‐pandemic. An association with HIV transmission risk was borderline significant (p = 0.055).Conclusions: Despite comparable annual rates of new HIV diagnoses, LD has been increasing during the COVID‐19 pandemic, resulting in more opportunistic infections and higher hospitalization rates, possibly reflecting pandemic‐related shortages in HIV testing and care facilities. Maintaining HIV testing opportunities and access to treatment during a pandemic is crucial so as not to impede WHO elimination goals and so as to prevent an increase in AIDS‐related morbidity and mortality.
- Open Access
- 13 October 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (20) , 12231
Comparative Analysis of Antibody Titers against the Spike Protein of SARS-CoV-2 Variants in Infected Patient Cohorts and Diverse Vaccination Regimes
The presence of neutralizing antibodies against SARS-CoV-2 correlates with protection against infection and severe COVID-19 disease courses. Understanding the dynamics of antibody development against the SARS-CoV-2 virus is important for recommendations on vaccination strategies and on control of the COVID-19 pandemic. This study investigates the dynamics and extent of α-Spike-Ab development by different vaccines manufactured by Johnson & Johnson, AstraZeneca, Pfizer-BioNTech and Moderna. On day 1 after vaccination, we observed a temporal low-grade inflammatory response. α-Spike-Ab titers were reduced after six months of vaccination with mRNA vaccines and increased 14 days after booster vaccinations to a maximum that exceeded titers from mild and critical COVID-19 and Long-COVID patients. Within the group of critical COVID-19 patients, we observed a trend for lower α-Spike-Ab titers in the group of patients who survived COVID-19. This trend accompanied higher numbers of pro-B cells, fewer mature B cells and a higher frequency of T follicular helper cells. Finally, we present data demonstrating that past infection with mild COVID-19 does not lead to long-term increased Ab titers and that even the group of previously infected SARS-CoV-2 patients benefit from a vaccination six months after the infection.
- 13 October 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (20) , 12231
Open AccessComparative Analysis of Antibody Titers against the Spike Protein of SARS-CoV-2 Variants in Infected Patient Cohorts and Diverse Vaccination Regimes
The presence of neutralizing antibodies against SARS-CoV-2 correlates with protection against infection and severe COVID-19 disease courses. Understanding the dynamics of antibody development against the SARS-CoV-2 virus is important for recommendations on vaccination strategies and on control of the COVID-19 pandemic. This study investigates the dynamics and extent of α-Spike-Ab development by different vaccines manufactured by Johnson & Johnson, AstraZeneca, Pfizer-BioNTech and Moderna. On day 1 after vaccination, we observed a temporal low-grade inflammatory response. α-Spike-Ab titers were reduced after six months of vaccination with mRNA vaccines and increased 14 days after booster vaccinations to a maximum that exceeded titers from mild and critical COVID-19 and Long-COVID patients. Within the group of critical COVID-19 patients, we observed a trend for lower α-Spike-Ab titers in the group of patients who survived COVID-19. This trend accompanied higher numbers of pro-B cells, fewer mature B cells and a higher frequency of T follicular helper cells. Finally, we present data demonstrating that past infection with mild COVID-19 does not lead to long-term increased Ab titers and that even the group of previously infected SARS-CoV-2 patients benefit from a vaccination six months after the infection.
- Open Access
- 18 June 2021
- Published by Springer Nature in Infection
- Vol. 49 (5) , 1039-1043
SARS-CoV-2 seroconversions and chains of infection in healthcare professionals in a German maximum care provider (The CoSHeP study)
Introduction: The CoSHeP study provides novel data on SARS-CoV-2 seroconversion rates in healthcare professionals (HP) at risk at the University Hospital Bonn, a maximum healthcare provider in a region of 900.000 inhabitants. Methods: Single-center, longitudinal observational study investigating rate of SARS-CoV-2 IgG seroconversion in HP at 2 time-points. SARS-CoV-2 IgG was measured with Roche Elecsys Anti-SARS-CoV-2 assay. Results: Overall, 150 HP were included. Median age was 35 (range: 19–68). Main operational areas were intensive care unit (53%, n = 80), emergency room (31%, n = 46), and infectious disease department (16%, n = 24). SARS-CoV-2-IgG was detected in 5 participants (3%) at inclusion in May/June 2020, and in another 11 participants at follow-up (December 2020/ January 2021). Of the 16 seropositive participants, 14 had already known their SARS-CoV-2 infection because they had performed a PCR-test previously triggered by symptoms. Trailing chains of infection by self-assessment, 31% (n = 5) of infections were acquired through private contacts, 25% (n = 4) most likely through semi-private contacts during work. 13% (n = 2) were assumed to result through contact with contagious patients, further trailing was unsuccessful in 31% (n = 5). All five participants positive for SARS-CoV-2 IgG at inclusion remained positive with a median of 7 months after infection. Discussion: Frontline HP caring for hospitalized patients with COVID-19 are at higher risk of SARS-CoV-2 infections. Noteworthy, based upon identified chains of infection most of the infections were acquired in private environment and semi-private contacts during work. The low rate of infection through infectious patients reveals that professional hygiene standards are effective in preventing SARS-CoV-2 infections in HP. Persisting SARS-CoV-2-IgG might indicate longer lasting immunity supporting prioritization of negative HP for vaccination.
- 18 June 2021
- Published by Springer Nature in Infection
- Vol. 49 (5) , 1039-1043
Open AccessSARS-CoV-2 seroconversions and chains of infection in healthcare professionals in a German maximum care provider (The CoSHeP study)
Introduction: The CoSHeP study provides novel data on SARS-CoV-2 seroconversion rates in healthcare professionals (HP) at risk at the University Hospital Bonn, a maximum healthcare provider in a region of 900.000 inhabitants. Methods: Single-center, longitudinal observational study investigating rate of SARS-CoV-2 IgG seroconversion in HP at 2 time-points. SARS-CoV-2 IgG was measured with Roche Elecsys Anti-SARS-CoV-2 assay. Results: Overall, 150 HP were included. Median age was 35 (range: 19–68). Main operational areas were intensive care unit (53%, n = 80), emergency room (31%, n = 46), and infectious disease department (16%, n = 24). SARS-CoV-2-IgG was detected in 5 participants (3%) at inclusion in May/June 2020, and in another 11 participants at follow-up (December 2020/ January 2021). Of the 16 seropositive participants, 14 had already known their SARS-CoV-2 infection because they had performed a PCR-test previously triggered by symptoms. Trailing chains of infection by self-assessment, 31% (n = 5) of infections were acquired through private contacts, 25% (n = 4) most likely through semi-private contacts during work. 13% (n = 2) were assumed to result through contact with contagious patients, further trailing was unsuccessful in 31% (n = 5). All five participants positive for SARS-CoV-2 IgG at inclusion remained positive with a median of 7 months after infection. Discussion: Frontline HP caring for hospitalized patients with COVID-19 are at higher risk of SARS-CoV-2 infections. Noteworthy, based upon identified chains of infection most of the infections were acquired in private environment and semi-private contacts during work. The low rate of infection through infectious patients reveals that professional hygiene standards are effective in preventing SARS-CoV-2 infections in HP. Persisting SARS-CoV-2-IgG might indicate longer lasting immunity supporting prioritization of negative HP for vaccination.
- Open Access
- 3 October 2020
- Published by Wiley in Liver International
- Vol. 40 (12) , 2978-2981
Obstacles to HBV functional cure: Late presentation in HIV and its impact on HBV seroconversion in HIV/HBV coinfection
Several cohorts have shown that long‐term tenofovir‐containing combination antiretroviral therapy (cART) leads to higher HBsAg seroclearance rates in HIV/HBV coinfected patients vs HBV‐monoinfected patients under tenofovir disoproxil fumarate (TDF)‐based therapy. We have analysed data on determinants of HBsAg loss in a retrospective multicentric cohort of 359 HIV/HBV coinfected patients. Median CD4 T‐cell count at baseline was 359/ul (321‐404), CDC stage was C in 20% (n = 70). Most patients (68%) were ART‐naïve when TDF‐ or tenofovir alafenamide (TAF)‐containing cART was initiated (baseline). After a median follow‐up of 11 years HBsAg loss had occurred in 66/359 (18%) patients. However, patients with stage CDC C (P ≤ .001), lower CD4 gain (P = .043) and not receiving TDF/FTC (P = .008) were less likely to lose HBsAg. Long‐term TDF‐containing cART appears to achieve higher rates of HBsAg seroclearance compared to published data for HBV monoinfected subjects. However, late presentation for HIV and poor immune recovery significantly impair HBV seroconversion rates.
- 3 October 2020
- Published by Wiley in Liver International
- Vol. 40 (12) , 2978-2981
Open AccessObstacles to HBV functional cure: Late presentation in HIV and its impact on HBV seroconversion in HIV/HBV coinfection
Several cohorts have shown that long‐term tenofovir‐containing combination antiretroviral therapy (cART) leads to higher HBsAg seroclearance rates in HIV/HBV coinfected patients vs HBV‐monoinfected patients under tenofovir disoproxil fumarate (TDF)‐based therapy. We have analysed data on determinants of HBsAg loss in a retrospective multicentric cohort of 359 HIV/HBV coinfected patients. Median CD4 T‐cell count at baseline was 359/ul (321‐404), CDC stage was C in 20% (n = 70). Most patients (68%) were ART‐naïve when TDF‐ or tenofovir alafenamide (TAF)‐containing cART was initiated (baseline). After a median follow‐up of 11 years HBsAg loss had occurred in 66/359 (18%) patients. However, patients with stage CDC C (P ≤ .001), lower CD4 gain (P = .043) and not receiving TDF/FTC (P = .008) were less likely to lose HBsAg. Long‐term TDF‐containing cART appears to achieve higher rates of HBsAg seroclearance compared to published data for HBV monoinfected subjects. However, late presentation for HIV and poor immune recovery significantly impair HBV seroconversion rates.
- 29 January 2019
- Published by Wiley in Haemophilia
- Vol. 25 (2) , E117-E120
Acute Hepatitis E Virus infection in a hemophilic patient with acquired inhibitor during immune tolerance therapy according to modified Bonn‐Malmö protocol
- 29 January 2019
- Published by Wiley in Haemophilia
- Vol. 25 (2) , E117-E120
Acute Hepatitis E Virus infection in a hemophilic patient with acquired inhibitor during immune tolerance therapy according to modified Bonn‐Malmö protocol